Orthofix Medical Stock Pattern Recognition Doji Star
| OFIX Stock | USD 11.99 0.29 2.48% |
| Symbol |
Recognition |
Orthofix Medical Technical Analysis Modules
Most technical analysis of Orthofix Medical help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Orthofix from various momentum indicators to cycle indicators. When you analyze Orthofix charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Stock Overview, Methodology & Data Sources
Methodology
Unless otherwise specified, financial data for Orthofix Medical is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Orthofix (USA Stocks:OFIX) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: This report references public filings and market reference sources and institutional disclosures, including U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Food & Drug Administration (FDA). Certain datasets may update with delay depending on source availability. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Orthofix Medical has active sell-side coverage. Source-validated coverage currently shows 5 approved analysts, while broader market-consensus totals may differ across providers due to methodology and update timing. 2 analysts have submitted revenue and/or earnings estimates that may be incorporated into Macroaxis consensus inputs where available. Representative analyst firms may include Stifel, J.P. Morgan, Bernstein Research, UBS Investment Research, Oppenheimer & Co., among others. Updates may occur throughout the day.
This content is curated and reviewed by:
Michael Smolkin - Member of Macroaxis Board of DirectorsBecome your own money manager
Did you try this?
Run Portfolio Diagnostics Now
Portfolio DiagnosticsUse generated alerts and portfolio events aggregator to diagnose current holdings |
| All Next | Launch Module |
Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Investor Favorites Invested few shares | |
 | Macroaxis Index Invested over 60 shares | |
 | Dividend Beast Invested over 40 shares | |
 | Momentum Invested few shares | |
 | Artificial Intelligence Invested few shares | |
 | Blockchain Invested few shares | |
 | Baby Boomer Prospects Invested over 20 shares | |
More Resources for Orthofix Stock Analysis
A structured review of Orthofix Medical often starts with core financial statements and trend context. Financial ratios provide a structured lens for assessing Orthofix Medical's profitability and growth trends. Below are reports that help frame Orthofix Medical Stock in context: Earnings Share -2.33 | Revenue Per Share | Quarterly Revenue Growth 0.02 | Return On Assets | Return On Equity |